selected scholarly activity
-
academic article
- Impact of oral anticoagulation in patients with atrial fibrillation at very low thromboembolic risk. Heart British Heart Journal. 106:845-851. 2020
- Shared Decision-Making for Anticoagulation in Atrial Fibrillation: Do Physicians Really Listen?. Canadian Journal of Cardiology. 36:459-461. 2020
- Variations in incidence of venous thromboembolism in low-, middle-, and high-income countries. Cardiovascular Research. 2020
- Blood loss from laboratory testing, anemia, and red blood cell transfusion in the intensive care unit: a retrospective study. Transfusion. 60:256-261. 2020
- Evidence-Based Minireview: Mortality and thrombosis in patients receiving prothrombin complex concentrates or andexanet alfa for the management of direct oral factor Xa inhibitor–associated major bleeding. Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program. 2019:204-208. 2019
- What we have learned about direct oral anticoagulant reversal. Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program. 2019:198-203. 2019
- Andexanet alfa for reversal of factor Xa inhibitors: a critical review of the evidence. Future Cardiology. 15:395-404. 2019
- Scientific and Standardization Committee Communication: Guidance document on the periprocedural management of patients on chronic oral anticoagulant therapy: Recommendations for standardized reporting of procedural/surgical bleed risk and patient‐specific thromboembolic risk. Journal of Thrombosis and Haemostasis. 17:1966-1972. 2019
- Venous Thromboembolism in Patients with Liver Cirrhosis: Findings from the RIETE (Registro Informatizado de la Enfermedad TromboEmbolica) Registry. Seminars in Thrombosis and Hemostasis. 45:793-801. 2019
- Resumption of anticoagulant therapy after anticoagulant-related gastrointestinal bleeding. Thrombosis Research. 180:86-86. 2019
- Risk of venous and arterial thrombosis in non-surgical patients receiving systemic tranexamic acid: A systematic review and meta-analysis. Thrombosis Research. 179:81-86. 2019
- Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors. New England Journal of Medicine. 380:1326-1335. 2019
- Refractory urticaria and the importance of diagnosing Schnitzler’s syndrome. BMJ Case Reports. 12:e228546-e228546. 2019
- Resumption of anticoagulant therapy after anticoagulant-related gastrointestinal bleeding: A systematic review and meta-analysis. Thrombosis Research. 175:102-109. 2019
- Idarucizumab for Dabigatran-Related Gastrointestinal Bleeds. Circulation. 139:757-759. 2019
- The Non-Vitamin K Antagonist Oral Anticoagulants in Heart Disease: Section V—Special Situations. Thrombosis and Haemostasis. 119:014-038. 2019
- Devices to Reduce the Volume of Blood Taken for Laboratory Testing in ICU Patients: A Systematic Review. Journal of Intensive Care Medicine. 088506661881037-088506661881037. 2018
- Weight-adjusted tinzaparin for the prevention of venous thromboembolism after bariatric surgery. Journal of Thrombosis and Haemostasis. 16:2008-2015. 2018
- Antiplatelet use in patients with essential thrombocythemia: A survey of opinion and Canadian practice. Thrombosis Research. 167:6-8. 2018
- The real-world outcomes of treating Polycythemia Vera: Physician adherence to treatment guidelines. Leukemia Research. 70:62-66. 2018
- Pharmacological reversal of the direct oral anticoagulants-A comprehensive review of the literature. Research and Practice in Thrombosis and Haemostasis. 2:251-265. 2018
- Management of direct oral anticoagulant associated bleeding: Results of a multinational survey. Thrombosis Research. 163:19-21. 2018
- 2017 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants. Journal of the American College of Cardiology. 70:3042-3067. 2017
- Warfarin resumption following anticoagulant-associated intracranial hemorrhage: A systematic review and meta-analysis. Thrombosis Research. 160:97-104. 2017
- Occult Amebic Liver Abscess as Cause of Extensive Inferior Vena Cava and Hepatic Vein Thrombosis. American Journal of Tropical Medicine and Hygiene. 97:1214-1217. 2017
- Safety, pharmacokinetics, and reversal of apixaban anticoagulation with andexanet alfa. Blood Advances. 1:1827-1838. 2017
- Assessing renal function in patients receiving DOACs: Cockcroft-Gault versus estimated glomerular filtration rate. Thrombosis Research. 157:165-166. 2017
- Benefits and Risks of Antithrombotic Therapy in Essential Thrombocythemia. Annals of Internal Medicine. 167:170-170. 2017
- Specific antidotes for bleeding associated with direct oral anticoagulants. British Medical Journal BMJ (Clinical research ed.). 357:j2216-j2216. 2017
- Current understanding of bleeding with ibrutinib use: a systematic review and meta-analysis. Blood Advances. 1:772-778. 2017
- Laboratory Assessment of the Anticoagulant Activity of Direct Oral Anticoagulants. Chest. 151:127-138. 2017
- Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors. New England Journal of Medicine. 375:1131-1141. 2016
- Prothrombin complex concentrates versus fresh frozen plasma for warfarin reversal A systematic review and meta-analysis. Thrombosis and Haemostasis. 116:879-890. 2016
- The risk of atrial fibrillation with ibrutinib use: a systematic review and meta-analysis. Blood. 128:138-140. 2016
- Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity. New England Journal of Medicine. 373:2413-2424. 2015
- Monitoring and reversal of direct oral anticoagulants. Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program. 2015:117-124. 2015
- Plasma versus prothrombin complex concentrate for warfarin-associated major bleeding: a systematic review. Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program. 2015:448-453. 2015
- A systematic review of contemporary trials of anticoagulants in orthopaedic thromboprophylaxis: suggestions for a radical reappraisal. Journal of Thrombosis and Thrombolysis. 40:231-239. 2015
- Managing target-specific oral anticoagulant associated bleeding including an update on pharmacological reversal agents. Journal of Thrombosis and Thrombolysis. 39:395-402. 2015
- What is the effect of rivaroxaban on routine coagulation tests?. Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program. 2014:334-336. 2014
- Laboratory Measurement of the Anticoagulant Activity of the Non–Vitamin K Oral Anticoagulants. Journal of the American College of Cardiology. 64:1128-1139. 2014
- Reversal of target-specific oral anticoagulants. Drug Discovery Today. 19:1465-1470. 2014
- How I treat target-specific oral anticoagulant–associated bleeding. Blood. 123:1152-1158. 2014
- Reversal of novel oral anticoagulants in patients with major bleeding. Journal of Thrombosis and Thrombolysis. 35:391-398. 2013
- Acute management of bleeding in patients on novel oral anticoagulants. European Heart Journal. 34:489-498. 2013
- Corrigendum. Journal of Thrombosis and Haemostasis. 11:221-221. 2013
- Thrombopoietin Receptor Agonists in Primary Immune Thrombocytopenia. Seminars in Hematology. 50:S18-S21. 2013
- Anticoagulants in cancer. Journal of Thrombosis and Haemostasis. 10:2230-2241. 2012
- Periprocedural Heparin Bridging in Patients Receiving Vitamin K Antagonists. Circulation. 126:1630-1639. 2012
- Acute Hepatic Necrosis and Ischemic Limb Necrosis. New England Journal of Medicine. 367:879-881. 2012
- Liver-kidney transplantation in primary hyperoxaluria type-1: case report and literature review.. International Journal of Organ Transplantation Medicine. 2:126-132. 2011
- Complete heart block following intentional carbamate ingestion. Canadian Journal of Cardiology. 25:e288-e290. 2009
- Type II Bidirectional Ventricular Tachycardia as a Mechanism of Termination of Sustained Ventricular Tachycardia. Journal of Cardiovascular Electrophysiology. 20:345-346. 2009
- Graft-versus-host disease following marrow transplantation for aplastic anemia: different impact of two GVHD prevention strategies. Bone Marrow Transplantation. 42:51-56. 2008
- Invasive pneumococcal disease in adult hematopoietic stem cell transplant recipients: a decade of prospective population-based surveillance. Bone Marrow Transplantation. 41:743-747. 2008
- Central Nervous System Complications after Allogeneic Hematopoietic Stem Cell Transplantation: Incidence, Manifestations, and Clinical Significance. Biology of Blood and Marrow Transplantation. 13:1369-1379. 2007
-
chapter
- Venous Thromboembolism. 2102-2112. 2018
-
conference paper
- Risks and Benefits of Antithrombotic Therapy in Polycythemia Vera: A Systematic Review. Thrombosis Research. 6-6. 2019
- Blood Loss From Laboratory Testing in the Intensive Care Unit and Transfusion: A Retrospective Study. Transfusion. 208A-208A. 2019
- Reducing Unnecessary Blood Tests in the Critically Ill (RUBIC): A Multi-Center Prospective Audit. American Journal of Respiratory and Critical Care Medicine. 2019
- Blood Loss Due to Laboratory Testing in Critical Care Patients: A Retrospective Cohort Study. Blood. 4885-4885. 2018
- Small-Volume Tubes to Reduce Transufusion (STRATUS): A Pilot Study. Blood. 825-825. 2018
- 2. Abstract Title: Risk of venous and arterial thrombosis in patients receiving tranexamic acid: A systematic review and meta-analysis. Thrombosis Research. 2-2. 2018
- Why do clinicians prescribe oral anticoagulation in patients with atrial fibrillation despite a low CHA2DS2-VASc score?. European Heart Journal. 1007-1008. 2018
- Why do clinicians withhold anticoagulation in patients with atrial fibrillation and CHA2DS2VASc score of 2 or higher?. European Heart Journal. 821-821. 2018
- Why do clinicians prescribe oral anticoagulation in patients with atrial fibrillation despite a low CHA2DS2-VASc score?. Acta Cardiologica. 484-485. 2018
- Why do clinicians withhold anticoagulation in patients with atrial fibrillation and CHA2DS2-Vasc score >= 2?. Acta Cardiologica. 481-482. 2018
- Efficacy and Safety of Weight-Adjusted Extended Duration Tinzaparin for Prevention of Post-Operative Venous Thromboembolism after Bariatric Surgery. Blood. 2015
- Non-Specific Hemostatic Agents (PCC, aPCC, rVIIa) for Reversal of Direct Oral Anticoagulant Effect in Patients with Major Bleeding Complications: A Retrospective Review. Blood. 2015
- Initiating thromboprophylaxis with rivaroxaban up to 26 h after elective knee arthroplasty does not increase the incidence of venous thromboembolism. Journal of Thrombosis and Haemostasis. 391-391. 2015
- Interventions to reduce blood loss from laboratory testing in critically ill patients and impact on transfusion: a systematic review. Journal of Thrombosis and Haemostasis. 974-975. 2015
- Efficacy and safety of weight-adjusted extended duration tinzaparin for prevention of post-operative venous thromboembolism after bariatric surgery. Journal of Thrombosis and Haemostasis. 821-821. 2013
- Reversal of oral direct thrombin and factor Xa inhibitors: a systematic review. Journal of Thrombosis and Thrombolysis. 413-413. 2013
- Perioperative Heparin Bridging in Patients Receiving Oral Anticoagulation: Meta-Analysis of Bleeding and Thromboembolic Rates. Blood. 545-545. 2011
- Perioperative heparin bridging in patients receiving oral anticoagulation: meta-analysis of bleeding and thromboembolic rates. Journal of Thrombosis and Haemostasis. 604-604. 2011
- 241: Neurological complications in the recipients of allogeneic hematopoietic cell transplant. Biology of Blood and Marrow Transplantation. 88-89. 2007
- Preliminary report of clinical efficacy of patient (pt) specific vaccination using purified idiotype protein in myeloma.. Blood. 704A-704A. 1999